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REGULAR ARTICLE
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Key Points
•Due to increased relapse
risk, survival after HCT in
MPN-BP is inferior to de
novo AML in remission
and post-MDS AML.
• Survival after HCT in
MPN-BP with active
leukemia is similar to de
novo AML with active
leukemia.
Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) forBCR-ABL12
myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid
leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML),
are unknown. Using the Center for International Blood and Marrow Transplant Research
(CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients
with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression
analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall
survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active
leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de
novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76])
due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS
Submitted 11 June 2020; accepted 10 August 2020; published online 2 October
2020. DOI 10.1182/bloodadvances.2020002621.
CIBMTR supports accessibility of research in accord with the National Institutes of
Health (NIH) Data Sharing Policy and the National Cancer Institute (NCI) Cancer
Moonshot Public Access and Data Sharing Policy. The CIBMTR only releases
deidentified data sets that comply with all relevant global regulations regarding privacy
and confidentiality.
The full-text version of this article contains a data supplement.
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(HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared
with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both
comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP
and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar
between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body
irradiation–based myeloablative conditioning was associated with higher NRM in both
comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and
post-MDS AML due to increased relapse. Relapse-prevention strategies are required to
optimize HCT outcomes in MPN-BP.
Introduction
Essential thrombocythemia (ET), polycythemia vera (PV), and primary
myelofibrosis (PMF) are the 3 classical BCR-ABL12 myeloprolifer-
ative neoplasms (MPNs) characterized by recurrent mutations in
JAK2, CALR, and MPL genes. Blastic transformation is 1 of the
dreaded complications of MPNs, and is defined as $20% blasts in
peripheral blood or bone marrow. This transformation is mostly
myeloblastic transformation, although lymphoblastic transformation
has been described. This phase of the disease is also referred to as
the blast phase (BP) of MPN (MPN-BP).1 MPN-BP has an extremely
poor prognosis, with median survival ,6 months2-4; allogeneic
hematopoietic cell transplantation (HCT) is the only known modality
associated with long-term remission in selected patients.
There is no prospective study evaluating the outcomes of HCT in
MPN-BP, and data are limited to small retrospective studies. Few
retrospective studies have compared the outcomes of secondary
acute myeloid leukemia (AML) with de novo AML. Due to the small
number of patients, these studies have reported the results of HCT
in MPN-BP combined with other forms of secondary AML, such as
AML after prior history of myelodysplastic syndrome (MDS; post-
MDS AML) or AML after bone marrow failure.5-7 The results from
these studies are contradictory as a single-center study described
similar outcomes of secondary AML in first remission (CR1)
compared with de novo AML.5 However, a large study from the
European Society for Blood and Marrow Transplantation (EBMT)
group described inferior results of secondary AML in CR1 in
comparison with de novo AML.7 Both of these studies had a small
proportion of MPN-BP patients, and categorization of MDS/MPN and
bone marrow failure disorders as 1 disease entity may have been
oversimplification and not representative of the true biology of
underlying antecedent hematological disorders. Although there are
no direct comparisons, patients withMPN-BP appear to have a distinct
biological profile compared with de novo AML. The spectrum of
genetic abnormalities in MPN-BP is different from de novo AML, as
a significant proportion of MPN-BP patients have poor-risk cytoge-
netics and mutations such as TP53 are enriched in this cohort
(McNamara et al8 and V.G., J. A. Kennedy, J. Capo-Chichi, manuscript
submitted, July 2020). Moreover, MPN patients also have a higher
burden of inflammation- and thrombosis-related comorbid conditions.9
Whether the modest outcomes of HCT in MPN-BP are related to
high-risk biological features of underlying disease, a higher burden
of associated comorbid conditions, or both is unclear. Therefore,
understanding the outcomes of HCT in MPN-BP in compari-
son with de novo AML and post-MDS AML after adjusting for
patient-, disease-, and transplant-related factors is of clinical interest.
Using the Center for International Blood and Marrow Transplant
Research (CIBMTR) database, we therefore evaluated the HCT
outcomes in MPN-BP with de novo AML and with post-MDS AML in
2 separate comparisons using multivariate regression analysis.
Patients and methods
Data source
The CIBMTR is a combined research program of the Medical
College of Wisconsin and the National Marrow Donor Program,
forming a voluntary network of .500 transplantation centers
worldwide that contributes detailed data on allogeneic and
autologous HCTs to a centralized statistical center. Observational
studies conducted by the CIBMTR are performed in compliance
with all applicable federal regulations pertaining to the protection of
human research participants. Protected health information used in
performance of such studies is collected and maintained in
CIBMTR’s capacity as a public health authority under the US
Health Insurance Portability and Accountability Act regulations.
Study cohorts
The study cohort included patients $40 years undergoing first
allogeneic HCT between 2001 and 2015 for MPN-BP. MPN
diagnoses were ET, PV, PMF, post-ET myelofibrosis, post-PV
myelofibrosis, or unclassifiable MPN (MPN-U). BP was defined as
$20% myeloblasts in peripheral blood and/or bone marrow.1
Patients with Philadelphia-positive or BCR-ABL1 MPNs, autolo-
gous transplants, transplants from syngeneic donors, cord blood
transplants, or ex vivo T-cell depletion were excluded. The same
inclusion and exclusion criteria were applied for selection of de novo
AML and post-MDS AML cohorts. Unrelated donor (URD) trans-
plant recipients were classified based on available HLA typing as
previously described; patients with no known disparity at HLA-A, -B,
-C, or -DRB1 were defined as well matched, and those with 1 locus
known or probable disparate with the donors were defined as
mismatched.10 The intensity of conditioning regimens was defined
according to CIBMTR consensus criteria.11 Results of cytogenetic
testing provided by the transplantation center were reviewed and
classified as favorable, intermediate, poor risk, and missing.12
Patients who had peripheral blood and bone marrow blasts ,5%
prior to HCT were considered as being “in remission,” whereas
those with peripheral blood and/or bone marrow blasts $5% were
considered as having “active leukemia.”
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Table 1. Baseline characteristics of study cohorts with MPN-BP and
de novo AML
Characteristic MPN-BP De novo AML P
No. of patients 177 4749
No. of centers 73 221
Patient-related
Age at HCT, median (range), y ,.01*
Median (min-max) 59 (40-82) 54 (40-78)
Age at HCT, n (%), y ,.01†
40-49 30 (17) 1658 (35)
50-59 73 (41) 1894 (40)
60-69 59 (33) 1077 (23)
$70 15 (8) 120 (3)
Sex, n (%) ,.01†
Male 116 (66) 2552 (54)
Female 61 (34) 2197 (46)
Karnofsky score, n (%) ,.01†
90-100 88 (50) 2888 (61)
,90 84 (47) 1664 (35)
Missing 5 (3) 197 (4)
HCT-CI, n (%) ,.01†
0 33 (19) 705 (15)
1-2 31 (18) 736 (15)
$3 50 (28) 867 (18)
N/A, before 2007 61 (34) 2377 (50)
Missing 2 (1) 64 (1)
Disease-related
Etiology of MPN at original diagnosis, n (%)
PV 46 (26) 0 (0.0)
ET 51 (29) 0 (0.0)
PMF 60 (34) 0 (0.20)
MPN-U 20 (11) 0 (0.0)
Time between diagnosis of MPN and AML,
n (%), y
Median (min-max) 3 (0.0-30) N/A
,2 70 (40) 0 (0.0)
2-5 28 (16) 0 (0.0)
.5 63 (36) 0 (0.0)
Missing 16 (9) 0 (0.0)
WBC at diagnosis, n (%), 3109/L .08†
,30 121 (68) 2864 (60)
30-100 31 (18) 859 (18)
.100 9 (5) 453 (10)
Missing 16 (9) 573 (12)
Cytogenetics, n (%) ,.01†
Favorable 1 (,1) 305 (6)
Intermediate 96 (54) 2910 (61)
Poor 67 (38) 1073 (23)
Not tested 5 (3) 134 (3)
Missing 8 (5) 327 (7)
Table 1. (continued)
Characteristic MPN-BP De novo AML P
Disease status at HCT, n (%) ,.01†
In remission‡ 101 (57) 3511 (74)
Active leukemia§ 76 (43) 1238 (26)
Time from diagnosis of AML to HCT,
median (min-max), mo
5 (,1-321) 6 (,1-215) ,.01*
Time from diagnosis of AML to HCT,
n (%), mo
,.01†
,6 105 (59) 2146 (45)
6-12 38 (21) 1246 (26)
.12 34 (19) 1357 (29)
Therapy-related, n (%)
Induction therapy ,.01†
713 6 other 100 (56) 2997 (63)
Cytarabine-based 18 (10) 233 (5)
Hypomethylating 7 (4) 49 (1)
Other 3 (2) 212 (4)
No therapy given 11 (6) 21 (,1)
Missing 38 (21) 1237 (26)
Transplant-related
Graft source, n (%) .05†
Bone marrow 22 (12) 864 (18)
Peripheral blood 155 (88) 3885 (82)
Donor type, n (%) .25†
HLA-identical sibling 54 (31) 1774 (37)
Other related 13 (7) 282 (6)
Well-matched URD 83 (47) 1952 (41)
Partially matched/mismatched URD 27 (15) 741 (16)
D-R sex match, n (%) .05†
M-M 76 (43) 1643 (35)
M-F 36 (20) 1257 (26)
F-M 39 (22) 891 (19)
F-F 25 (14) 922 (19)
Missing 1 (,1) 36 (,1)
D-R CMV status, n (%) .06†
1/1 49 (28) 1566 (33)
1/2 13 (7) 468 (10)
2/1 58 (33) 1489 (31)
2/2 53 (30) 1038 (22)
Missing 4 (2) 188 (4)
Conditioning regimen, n (%) .01†
TBI-MAC 21 (12) 971 (20)
Chemo-MAC 72 (41) 1912 (40)
RIC/NST 84 (47) 1866 (39)
CNI, calcineurin inhibitor; Chemo-MAC, chemotherapy-based MAC; CMV, cytomegalovirus; D-R,
donor-recipient; F, female; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; HCT-CI, Hematopoietic Cell Transplantation-specific
Comorbidity Index; M, male; MAC, myeloablative conditioning; max, maximum; min, minimum; MTX,
methotrexate; N/A, not applicable; NST, nonmyeloablative allogeneic stem cell transplantation; RIC,
reduced-intensity conditioning; TBI-MAC, TBI-based MAC; WBC, white blood cell.
*Hypothesis testing: Kruskal-Wallis test.
†Hypothesis testing: Pearson x2 test.
‡In remission, CR1/CR2 for de novo AML and blasts ,5% for MPN-BP and post-MDS AML.
§Active leukemia, blasts in bone marrow or peripheral blood $5%.
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End points
The primary end point of the study was overall survival (OS), defined
as time from HCT to death from any cause. Patients were censored
at the last follow-up. Other end points of interest were acute graft-
versus-host disease (aGVHD), chronic GVHD (cGVHD), non-
relapse mortality (NRM), relapse, and progression-free survival
(PFS). aGVHD and cGVHD were diagnosed and graded
according to consensus criteria.13,14 Relapse was reported by
the transplantation centers, with NRM considered a competing
event. NRM was defined as death from any cause other than
relapse without evidence of disease relapse, and relapse was
considered a competing event. PFS was defined as time from
HCT to progression, relapse, or death.
Statistical analysis
Descriptive statistical tables of patients including demographics,
disease-related factors, and transplant-related factors of the study
cohorts were prepared. The univariate probability of OS and PFS
was calculated using the Kaplan-Meier estimator, with the variance
estimated by the Greenwood formula and P value from the log-rank
test. Univariate probabilities of aGVHD, cGVHD, NRM, and relapse
were calculated based on cumulative incidence rates to accommodate
competing risks. The Gray test P values were calculated to evaluate
the differences across cumulative incidence functions. Multivariable
regression analysis was performed using the Cox proportional
hazards model. The comparisons of MPN-BP vs de novo AML, and
MPN-BP vs post-MDS AML, were investigated separately for the
following outcomes: OS, aGVHD, cGVHD, NRM, relapse, and
PFS with adjustments for patient-related, disease-related, and
transplant-related variables. The proportionality assumption of
the Cox regression model was tested using time-dependent
covariate of the main effect (MPN-BP vs de novo AML, and MPN-
BP vs post-MDS AML). A forward stepwise selection procedure
was used to identify significant covariates. Potential interactions
between the main effect and other significant covariates were
tested.
Variables considered in the multivariate analysis
The following patient-, disease-, and transplant-related variables were
included in the multivariate analysis: age at HCT, sex, performance
scores (,90 vs $90), cytogenetic abnormalities (favorable/interme-
diate vs poor vs missing), disease status prior to HCT (in remission vs
active leukemia), donor type (matched sibling donor vs well-matched
URD vs partially or mismatched URD vs other related donor),
conditioning intensity (total-body irradiation [TBI]-based myeloablative
vs chemotherapy-based myeloablative vs reduced intensity), graft type
(peripheral blood vs bone marrow), GVHD prophylaxis (calcineurin
inhibitor [CNI] plus methotrexate plus or minus others vs CNI plus
mycophenolate mofetil [MMF] plus or minus others vs CNI alone
vs others), antithymocyte globulin or alemtuzumab (Campath) (yes
vs no), donor-recipient sex match (male-male vs male-female vs
female-male vs female-female), donor-recipient cytomegalovirus
(CMV) status (1/1 vs 1/2 vs 2/1 vs 2/2), and year of HCT
(2001-2005 vs 2006-2010 vs 2011-2015).
Results
Patient, disease, and transplantation characteristics
A total of 6030 patients met study eligibility criteria as follows:
177 post-MPN BP, 4749 de novo AML, and 1104 post-MDS AML
(Tables 1 and 2). Median follow-up of survivors was 71 months,
78 months, and 94 months in the MPN-BP, de novo AML, and post-
MDS AML cohorts, respectively. Tables 1 and 2 shows detailed
patient-, disease-, and transplantation-related characteristics of
the study cohorts. A higher proportion of patients with MPN-BP
had poor-risk karyotype (38%) in comparison with de novo AML
(23%) and post-MDS AML (34%). Active leukemia at HCT was
seen in 43%, 26%, and 38% of patients with MPN-BP, de novo
AML, and post-MDS AML, respectively (P , .001) (Tables 1 and
2). There was significant reduction in patients undergoing HCT
with active leukemia (MPN-BP, 61%, 40%, and 35% [P5 .02]; de
novo AML, 51%, 37%, and 23% [P , .01]; post-MDS AML, 34%,
25%, and 17% [P, .01]) in the 3 time periods between 2001 and
2005, 2006 and 2010, and 2011 and 2015, respectively.
Comorbidity data as assessed by the Hematopoietic Cell
Transplantation-specific Comorbidity Index (HCT-CI) were available
after 2007 and HCT-CI scores $3 were seen in 28%, 18%, and
22% in patients with MPN-BP, de novo AML, and post-MDS AML,
respectively (Tables 1 and 2). The median duration of underlying
hematologic disorder was significantly longer in MPN-BP patients
compared with post-MDS AML (3 years vs 0.29 years; P , .001)
(Tables 1 and 2).
Table 1. (continued)
Characteristic MPN-BP De novo AML P
GVHD prophylaxis, n (%) .39†
CNI 1 MMF 6 others 47 (27) 1091 (23)
CNI 1 MTX 6 others 99 (56) 2833 (60)
CNI 6 others 19 (11) 565 (12)
Post-CY 10 (6) 157 (3)
Other 1 (,1) 42 (,1)
Missing 1 (,1) 61 (1)
In vivo T-cell depletion, n (%) .64†
No 131 (74) 3440 (72)
Yes 46 (26) 1309 (28)
Planned G-CSF/GM-CSF within 7 d
post-HCT, n (%)
.81†
No 129 (73) 3504 (74)
Yes 46 (26) 1167 (25)
Missing 2 (1) 78 (2)
Year of transplant, n (%) ,.01†
2001-2005 39 (22) 1600 (34)
2006-2010 72 (41) 1958 (41)
2011-2015 66 (37) 1191 (25)
Follow-up, median (min-max), mo 71 (14-169) 78 (1-198)
CNI, calcineurin inhibitor; Chemo-MAC, chemotherapy-based MAC; CMV, cytomegalovirus; D-R,
donor-recipient; F, female; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; HCT-CI, Hematopoietic Cell Transplantation-specific
Comorbidity Index; M, male; MAC, myeloablative conditioning; max, maximum; min, minimum; MTX,
methotrexate; N/A, not applicable; NST, nonmyeloablative allogeneic stem cell transplantation; RIC,
reduced-intensity conditioning; TBI-MAC, TBI-based MAC; WBC, white blood cell.
*Hypothesis testing: Kruskal-Wallis test.
†Hypothesis testing: Pearson x2 test.
‡In remission, CR1/CR2 for de novo AML and blasts ,5% for MPN-BP and post-MDS AML.
§Active leukemia, blasts in bone marrow or peripheral blood $5%.
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Table 2. Baseline characteristics of study cohorts with MPN-BP and
post-MDS AML
Characteristic MPN-BP Post-MDS AML P
No. of patients 177 1104
No. of centers 73 165
Patient-related
Age at HCT, y .78*
Median (min-max) 59 (40-82) 59 (40-76)
Age at HCT, n (%), y .31†
40-49 30 (17) 196 (18)
50-59 73 (41) 429 (39)
60-69 59 (33) 419 (38)
$70 15 (8) 60 (5)
Sex, n (%) .30†
Male 116 (66) 679 (62)
Female 61 (34) 425 (38)
Karnofsky score, n (%) .53†
90-100 88 (50) 579 (52)
,90 84 (47) 481 (44)
Missing 5 (3) 44 (4)
HCT-CI, n (%) .14†
0 33 (19) 175 (16)
1-2 31 (18) 195 (18)
$3 50 (28) 240 (22)
N/A, before 2007 61 (34) 469 (42)
Missing 2 (1) 25 (2)
Disease-related
Etiology of MPN at original diagnosis, n (%)
PV 46 (26) 0 (0.0)
ET 51 (29) 0 (0.0)
PMF 60 (34) 0 (0.0)
MPN-U 20 (11) 0 (0.0)
N/A 0 (0.0) 1104 (100)
Time between diagnosis of MPN/MDS and
AML, n (%), y
Median (min-max) 3 (0.0-30) 0.3 (0.0-23)
,2 70 (40) 764 (69)
2-5 28 (16) 71 (6)
.5 63 (36) 29 (3)
Missing 16 (9) 240 (22)
WBC at diagnosis, n (%), 3109/L ,.01†
,30 121 (68) 894 (81)
30-100 31 (18) 95 (9)
.100 9 (5) 21 (2)
Missing 16 (9) 94 (9)
Cytogenetics, n (%) .76†
Favorable 1 (,1) 14 (1)
Intermediate 96 (54) 642 (58)
Poor 67 (38) 371 (34)
Not tested 5 (3) 29 (3)
Missing 8 (5) 48 (4)
Table 2. (continued)
Characteristic MPN-BP Post-MDS AML P
Disease status at HCT, n (%) .21†
In remission‡ 101 (57) 685 (62)
Active leukemia§ 76 (43) 419 (38)
Time from diagnosis to HCT,
median (min-max)
5 (0.3-321) 5 (0.2-108) .13*
Time from diagnosis of AML to HCT,
n (%), mo
.43†
,6 105 (59) 681 (62)
6-12 38 (21) 253 (23)
.2 34 (19) 170 (15)
Therapy-related, n (%)
Induction therapy .30†
713 6 other 100 (56) 568 (51)
Cytarabine based 18 (10) 99 (9)
Hypomethylating 7 (4) 41 (4)
Other 3 (2) 62 (6)
No therapy given 11 (6) 69 (6)
Missing 38 (21) 265 (24)
Transplant-related
Graft source, n (%) .15†
Bone marrow 22 (12) 185 (17)
Peripheral blood 155 (88) 919 (83)
Donor type, n (%) .47†
HLA-identical sibling 54 (31) 344 (31)
Other related 13 (7) 51 (5)
Well-matched URD 83 (47) 522 (47)
Partially matched/mismatched URD 27 (15) 187 (17)
D-R sex match, n (%) .84†
M-M 76 (43) 464 (42)
M-F 36 (20) 250 (23)
F-M 39 (22) 212 (19)
F-F 25 (14) 174 (16)
Missing 1 (,1) 4 (,1)
D-R CMV status, n (%) .12†
1/1 49 (28) 344 (31)
1/2 13 (7) 104 (9)
2/1 58 (33) 382 (35)
2/2 53 (30) 235 (21)
Missing 4 (2) 39 (4)
Conditioning regimen, n (%) .54†
TBI-MAC 21 (12) 157 (14)
Chemo-MAC 72 (41) 408 (37)
RIC/NST 84 (47) 539 (49)
*Hypothesis testing: Kruskal-Wallis test.
†Hypothesis testing: Pearson x2 test.
‡In remission, CR1/CR2 for de novo AML and blasts ,5% for MPN-BP and post-MDS
AML.
§Active leukemia, blasts in bone marrow or peripheral blood $5%.
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Transplantation outcomes
Comparison of outcomes in MPN-BP vs de novo AML.
Univariate comparisons for various transplant outcomes between
MPN-BP patients vs de novo AML are shown in supplemental
Table 1. In a multivariate analysis, there was no difference in grade
II-IV aGVHD, grade III-IV aGVHD, and cGVHD between patients
undergoing HCT for MPN-BP vs de novo AML (Table 3). In
a multivariable analysis comparing MPN-BP with de novo AML,
disease status at HCT had a significant interaction with the main
variable (Table 3). The OS of MPN-BP patients in remission was
significantly inferior to de novo AML patients in remission (hazard
ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]; P 5
.003) (Figure 1A), whereas OS was similar in MPN-BP patients with
active leukemia compared with de novo AML patients (HR, 0.93
[95% CI, 0.72-1.20]; P 5 .59) (Figure 1B). The relapse rate in
MPN-BP patients in remission was significantly higher compared
with de novo AML in remission (HR, 2.18 [95% CI, 1.69-2.8]; P ,
.0001) (Figure 1C), whereas no difference in relapse rate was seen
in MPN-BP patients with active leukemia vs de novo AML patients
with active leukemia (HR, 1.16 [95% CI, 0.88-1.54]; P 5 .30)
(Figure 1D). No difference in NRM was observed between the 2
cohorts (Table 3). Other factors associated with transplant
outcomes in this comparison are summarized in supplemental
Table 3. Of note, older age and male sex were associated with
inferior OS due to higher NRM. Poor performance status and poor-
risk cytogenetics were associated with inferior OS, higher relapse
risk, and higher NRM. Due to higher NRM, TBI-based myeloablative
conditioning (MAC; TBI-MAC) had inferior survival in comparison
with chemotherapy-based MAC (Chemo-MAC) or reduced-intensity
conditioning (RIC) (supplemental Table 2). NRM was also higher in
patients using cyclosporine (CSA) and MMF (CSA-MMF)-based
GVHD prophylaxis compared with CSA and methotrexate (supple-
mental Table 2). Patients using CSA-MMF had a higher risk of grade
II-IV and grade III-IV aGVHD (data not shown). In vivo T-cell depletion
was associated with lower NRM (supplemental Table 2).
Comparison of outcomes in MPN-BP vs post-MDS AML.
Univariate comparisons for various transplant outcomes between
MPN-BP patients vs post-MDS AML according to disease status
are shown in supplemental Table 3. In a multivariate analysis, there
was no difference in grade II-IV aGVHD, grade II-IV aGVHD, and
cGVHD between patients undergoing HCT for MPN-BP vs de novo
AML (Table 4). In a multivariable analysis comparing MPN-BP with
Table 2. (continued)
Characteristic MPN-BP Post-MDS AML P
GVHD prophylaxis, n (%) .38†
CNI 1 MMF 6 others 47 (27) 313 (28)
CNI 1 MTX 6 others 99 (56) 619 (56)
CNI 6 others 19 (11) 118 (11)
Post-CY 10 (6) 30 (3)
Other 1 (,1) 16 (1)
Missing 1 (,1) 8 (,1)
In vivo T-cell depletion, n (%) .05†
No 131 (74) 735 (67)
Yes 46 (26) 369 (33)
Planned G-CSF/GM-CSF within 7 d
post-HCT, n (%)
.18†
No 129 (73) 844 (76)
Yes 46 (26) 231 (21)
Missing 2 (1) 29 (3)
Year of transplant, n (%) ,.01†
2001-2005 39 (22) 347 (31)
2006-2010 72 (41) 489 (44)
2011-2015 66 (37) 268 (24)
Follow-up, median (min-max) 71 (14-169) 94 (3-193)
*Hypothesis testing: Kruskal-Wallis test.
†Hypothesis testing: Pearson x2 test.
‡In remission, CR1/CR2 for de novo AML and blasts ,5% for MPN-BP and post-MDS
AML.
§Active leukemia, blasts in bone marrow or peripheral blood $5%.
Table 3. Multivariate Cox model for study cohorts undergoing HCT
for MPN-BP vs de novo AML
n HR (95% CI) P
aGVHD II-IV
De novo AML 4693 1.00 (Reference) .32
MPN-BP 176 1.12 (0.90-1.40)
aGVHD III-IV
De novo AML 4677 1.00 (Reference) .44
MPN-BP 174 1.14 (0.81-1.60)
cGVHD
De novo AML 4693 1.00 (Reference) .47
MPN-BP 176 1.05 (0.93-1.18)
OS
In remission*
De novo AML 3511 1.00 (Reference) .003
MPN-BP 101 1.40 (1.12 - 1.76)
Active leukemia†
De novo AML 1238 1.00 (Reference) .59
MPN-BP 76 0.93 (0.72 - 1.20)
Relapse
In remission*
De novo AML 3461 1.00 (Reference) ,.0001
MPN-BP 101 2.18 (1.69-2.80)
Active leukemia†
De novo AML 1208 1.00 (Reference) .30
MPN-BP 76 1.16 (0.88 - 1.54)
NRM
De novo AML 4669 1.00 (Reference) .92
MPN-BP 177 1.02 (0.74-1.41)
PFS
De novo AML 4669 1.00 (Reference) .0003
MPN-BP 177 1.35 (1.15-1.59)
CI, confidence interval; HR, hazard ratio.
*In remission: CR1/CR2 for de novo AML and blasts ,5% in peripheral blood and bone
marrow for MPN-BP and post-MDS AML.
†Active leukemia: blasts in peripheral blood or bone marrow ,5%.
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post-MDS AML, OS of MPN-BP patients was inferior to post-MDS
AML patients (HR, 1.19 [95% CI, 1.00-1.43]; P 5 .05) (Figure 2A)
due to increased relapse rate in MPN-BP (HR, 1.60 [95% CI,
1.31-1.96]; P , .0001) (Figure 2B). No difference in NRM was
seen in MPN-BP patients compared with those with post-MDS
AML (HR, 1.16 [95% CI, 0.88-1.54]; P 5 .30) (Table 3). Other
factors associated with transplant outcomes in this comparison
are summarized in supplemental Table 4. As expected, older age
was associated with inferior OS due to higher NRM. Poor
performance status and poor-risk cytogenetics were associated
with inferior OS due to higher relapse risk. TBI-MAC was
associated with inferior survival in comparison with Chemo-MAC
or RIC due to higher NRM. Peripheral blood as the graft source
was associated with better survival due to lower relapse rate
(supplemental Table 4). Patients using CSA-MMF–based GVHD
prophylaxis had higher NRM compared with CSAand methotrex-
ate (supplemental Table 4). In vivo T-cell depletion was associated
with lower NRM.
Discussion
In the current study, we evaluated the outcomes of HCT in MPN-
BP with de novo AML and with post-MDS AML in 2 separate
comparisons. Although NRM was similar between these cohorts,
the relapse rate was significantly higher in MPN-BP in remission
compared with de novo AML in remission, and MPN-BP vs post-
MDS AML. Similar outcomes were observed in patients with MPN-
BP with active leukemia compared with de novo AML with active
leukemia. We also observed that there is consistent reduction in the
transplant activity for patients with active leukemia at the time of
HCT for MPN-BP, de novo AML, and post-MDS AML cohorts,
respectively.
Biologically, patients with MPN-BP are significantly distinct from
de novo AML.8,15,16 Patients with MPN-BP have a complex
genetic profile with a higher frequency of adverse-risk cytogenetic
abnormalities as well as mutations known to affect the outcomes of
AML patients such as TP53, RAS-signaling pathway mutations, and
ASXL1 and SRSF2 mutations. A very high rate of relapse seen in
the early posttransplant period in patients with MPN-BP is likely
related to these adverse biological factors. In addition, remission in
MPN-BP is very different compared with the remission in de novo
AML and mainly conversion of BP to chronic phase of the disease.
We have previously reported that, at the molecular level, there was
no difference in molecular profiling of MPN-BP patients in remission
vs MPN-BP with active leukemia, and mutation spectrum, variant
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Figure. 1. Comparative outcomes of MPN-BP vs de novo AML. (A) Adjusted probability of OS of MPN-BP vs de novo AML in remission. The OS of MPN-BP patients in
remission was significantly inferior to de novo AML patients in remission (HR, 1.40 [95% CI, 1.12-1.76]; P 5 .003). (B) Adjusted probability of OS of MPN-BP vs de novo AML
with active leukemia. The OS was similar in MPN-BP patients with active leukemia compared with de novo AML patients with active leukemia (HR, 0.93 [95% CI, 0.72-1.20];
P 5 .59). (C) Adjusted cumulative incidence of relapse of MPN-BP vs de novo AML in remission. The relapse rate in MPN-BP patients in remission was significantly higher
compared with de novo AML in remission (HR, 2.18 [95% CI, 1.69-2.8]; P , .0001). (D) Adjusted cumulative incidence of relapse of MPN-BP vs de novo AML with active
leukemia. No difference in relapse rate was seen in MPN-BP patients with active leukemia vs de novo AML patients with active leukemia (HR, 1.16 [95% CI, 0.88-1.54];
P 5 .30).
4754 GUPTA et al 13 OCTOBER 2020 x VOLUME 4, NUMBER 19
D
ow
nloaded from
 http://ashpublications.org/bloodadvances/article-pdf/4/19/4748/1761619/advancesadv2020002621.pdf by guest on 21 O
ctober 2020
allele frequency, and residual burden of mutations was similar in
these 2 cohorts.17 In comparison with post-MDS AML patients,
MPN-BP patients also had significantly longer duration of the
underlying hematologic disorder. Longer duration of the underlying
hematologic disorder can potentially add to comorbid illnesses,
and indeed in the MPN-BP cohort, burden of comorbidities, as
measured by HCT-CI, was significantly higher. Underlying comorbid
conditions perhaps led to the higher proportion of patients with
poor performance status in the MPN-BP cohort.
This study has several limitations as inherent to any retrospective
registry-based studies, and caution needs to be exercised in the
interpretation of the results. Remission status was based on basic
morphological criteria, and there was no central review of bone
marrow. Detailed granular data needed for response assessment
using international working group criteria were not collected in the
CIBMTR database. Comorbidity data were missing in one-third of
the patients with MPN-BP, therefore we were unable to adjust for
this in the multivariate analysis. Nevertheless, this study signifi-
cantly adds to the understanding of outcomes of HCT in MPN-BP.
Previous reported studies were limited by small patient numbers,
short follow-up, and primarily descriptive nature.18-20 Furthermore,
multivariate analysis was either not done18 or had insufficient
power19,20 and the median follow-up was shorter. The current
study has a significantly larger number of patients with mature
follow-up.
Several noteworthy findings in this study may guide clinical prac-
tice and patient counseling and optimize transplant protocols. The
relapse rate was lower with peripheral blood grafts in patients with
MPN-BP and post-MDS AML. NRMwas similar between MPN-BP vs
de novo AML, andMPN-BP vs post-MDSAML.We also demonstrate
that a TBI-MAC regimen is associated with higher NRM in both
comparisons, and therefore should be avoided in these patients.
No significant difference in OS was observed with Chemo-MAC
vs RIC. An EBMT study recommended MAC for AML secondary
to MPN/MDS as increased relapse was observed after 6 months in
patients undergoingRIC.6However, the EBMT study did not differentiate
between TBI-MAC vs Chemo-MAC. In our study, higher NRM was
associated with CSA-MMF–based GVHD prophylaxis and lower
NRM with T-cell depletion strategies in both comparisons. These
findings suggest the need for optimization of GVHD-prevention
strategies.
In summary, we demonstrate that HCT outcomes are similar in
MPN-BP patients with active leukemia compared with de novo
AML with active leukemia. Due to increased relapse risk, the
survival of MPN-BP patients in remission is significantly inferior to
de novo AML in remission and in comparison with post-MDS AML.
Table 4. Multivariate Cox model for study cohorts undergoing HCT
for MPN-BP vs post-MDS AML
n HR (95% CI) P
aGVHD II-IV
MDS-AML 1090 1.00 (Reference) .98
MPN-BP 176 1.00 (0.79-1.27)
aGVHD III-IV
MDS-AML 1086 1.00 (Reference) .94
MPN-BP 174 0.99 (0.69-1.41)
cGVHD
MDS-AML 1091 1.00 (Reference) .32
MPN-BP 176 0.88 (0.67-1.14)
OS
Post-MDS AML 1104 1.00 (Reference) .05
MPN-BP 177 1.19 (1.00-1.43)
Relapse
Post-MDS AML 1085 1.00 (Reference) ,.0001
MPN-BP 177 1.60 (1.31-1.96)
NRM
Post-MDS AML 1085 1.00 (Reference) .81
MPN-BP 177 0.96 (0.69-1.34)
PFS
Post-MDS AML 1085 1.00 (Reference) .0003
MPN-BP 177 1.38 (1.16-1.63)
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Figure. 2. Comparative outcomes of MPN-BP vs
post-MDS AML. (A) Adjusted probability of OS of
MPN-BP vs post-MDS AML. The OS of MPN-BP
patients was inferior to post-MDS AML patients
(HR, 1.19 [95% CI, 1.00-1.43]; P 5 .05). (B) Ad-
justed cumulative incidence of relapse of MPN-BP vs
post-MDS AML. The relapse rate in MPN-BP patients
is significantly higher as compared with post-MDS
AML (HR, 1.60 [95% CI, 1.31-1.96]; P , .0001).
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Relapse-prevention strategies are required to improve the out-
comes of MPN-BP patients undergoing HCT.
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